Premium
Personalizing Antiplatelet Therapy With Clopidogrel
Author(s) -
Trenk D,
Zolk O,
Fromm M F,
Neumann FJ,
Hochholzer W
Publication year - 2012
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2012.133
Subject(s) - clopidogrel , medicine , aspirin , percutaneous coronary intervention , clinical pharmacology , prasugrel , acute coronary syndrome , ticlopidine , p2y12 , ticagrelor , cardiology , platelet , loading dose , platelet aggregation inhibitor , intensive care medicine , pharmacology , myocardial infarction
Dual antiplatelet therapy with aspirin and clopidogrel is the accepted standard for prevention of ischemic complications after percutaneous coronary intervention and has been shown to reduce cardiovascular events in patients with acute coronary syndromes (ACSs). There is substantial interindividual variability in antiplatelet response to clopidogrel. Various clinical studies have demonstrated that patients with high on‐clopidogrel platelet reactivity incur an increased risk for ischemic events. In recent years, several clinical and demographic variables as well as multiple genetic factors contributing to the variability in antiplatelet response to clopidogrel have been identified. We discuss strategies based on platelet function testing or genotyping for improvement of antiplatelet effects of clopidogrel and thereby clinical outcome. Clinical Pharmacology & Therapeutics (2012); 92 4, 476–485. doi: 10.1038/clpt.2012.133